Latest News EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering By Staff Friday, December 8, 2023 12:21 AM WATERTOWN, Mass.—EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, announced the pricing of an underwritten public offering of 11,764,706 shares of its common stock at a public offering price of $17 per share. The aggregate gross proceeds from this offering are expected to be approximately $200 million, before deducting underwriting discounts and commissions and other offering expenses payable by EyePoint. All of the shares of common stock are being sold by EyePoint.The closing of the offering is expected to occur on or about Dec. 8, 2023, subject to the satisfaction of customary closing conditions. In addition, EyePoint has granted the underwriters an option for a period of 30 days to purchase up to an additional 1,764,705 shares of EyePoint’s common stock at the public offering price, less underwriting discounts and commissions.J.P. Morgan, TD Cowen and Guggenheim Securities are acting as joint book running managers for the offering. Cantor is also acting as a book running manager for the offering. Mizuho and Laidlaw & Company (UK) Ltd. are acting as co-managers for the offering.EyePoint intends to use the net proceeds that it will receive from the offering to advance clinical development of EYP-1901 for wet age related macular degeneration through the initiation of and reporting of topline data from two pivotal Phase 3 clinical trials, as well as support its earlier stage pipeline development initiatives, and for general corporate purposes, according to the company.